The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

February 2, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The U.S. Food & Drug Administration (FDA) approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin (IL) 1 receptor antagonist (DIRA). The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.

You Might Also Like
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
Also By This Author
  • Tocilizumab Promising for sJIA

Anakinra Approved for DIRA
In late December 2020, the FDA approved anakinra (Kineret) to treat deficiency of interleukin (IL) 1 receptor antagonist (DIRA). DIRA is a rare, autoinflammatory disease that occurs during the first weeks of life and is caused by a genetic mutation in the IL1RN gene that encodes for this specific receptor. Patients with this deficiency get unopposed IL-1 signaling that leads to a life-threatening systemic inflammatory response, affecting the bones and skin.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In November 2001, the FDA initially approved anakinra to treat the signs and symptoms of moderate to severe active rheumatoid arthritis in adults for whom one or more disease-modifying anti-rheumatic drugs were ineffective.2 The treatment was subsequently approved for treating neonatal-onset multi-system inflammatory disease.3

Background: Research supporting this latest FDA approval included patients (N=9) aged 1 month to 9 years old who were evaluated in a long-term natural history study and treated for up to 10 years. These patients received a range of anakinra doses, from 1 mg/kg/day up to 7.5 mg/kg per day.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

All study patients attained inflammatory remission, defined as a C-reactive protein level of less than or equal to 5 mg/L. No inflammatory bone disease or pustulosis, and no concomitant glucocorticoid use were reported. The most common adverse events were fever, flu-like illness, gastroenteritis, rash and upper respiratory infection.

During this study, anakinra’s safety profile was consistent with that seen when treating neonatal-onset multi-system inflammatory disease. No new safety signals were identified.

FDA Approves Rituximab Biosimilar
On Dec. 17, 2020, the FDA approved Riabni (rituximab-arrx), which is biosimilar to Rituxan (rituximab).4 This agent is approved to treat adults with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Swedish Orphan Biovitrum AB. News release: FDA approves Kineret (anakinra) for the treatment of deficiency of IL-1 receptor antagonist (DIRA). 2020 Dec 22.
  2. U.S. Food & Drug Administration. Product approval letter: Kineret. 2001 Nov 14.
  3. Swedish Orphan Biovitrum AB. Package labeling Kineret (anakinra). 2020 Dec.
  4.      Amgen. News release: FDA approves Amgen’s Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab). 2020 Dec 17.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: anakinra, deficiency of interleukin 1 receptor antagonist (DIRA), FDA, FDA approval, Riabni, rituximab-arrx, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
  • U.S. FDA Approves Biosimilar to Etanercept

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.